CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
Cold-adapted live attenuated influenza vaccine (FluMist) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00091702
NCT00091702Phase 2Completed
CompareCT.gov

A Phase I/II Randomized Trial of the Safety and Immunogenicity of Cold Adapted Influenza Vaccine (FluMist) in HIV-Infected Children and Adolescents

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Sep 20, 2004·Updated Nov 1, 2021

In Brief

A Phase 2 clinical trial evaluating Cold-adapted live attenuated influenza vaccine (FluMist) and Inactivated influenza vaccine (IAIV) for HIV Infections and Influenza. Completed, across 61 sites in 2 countries.

Detailed Summary

The purpose of this study is to compare two flu vaccines to determine their safety and ability to stimulate an immune response in HIV infected children and adolescents. This study will also determine how often and how long people who receive a vaccine are able to spread flu vaccine virus to other people.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections, Influenza
CountriesPuerto Rico, United States
CollaboratorsEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 20, 2004
Study CompletionJan 1, 2006
TodayJul 2, 2026
Posted 21.8 years ago

Interventions

Cold-adapted live attenuated influenza vaccine (FluMist)biological

Inactivated influenza vaccine (IAIV)biological